<DOC>
	<DOCNO>NCT01440686</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics pharmacodynamics HL-032 oral administration healthy male volunteer .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics Study HL-032 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<criteria>Healthy male subject Age ( yr ) 19 50 Signed write informed consent Known hypersensitivity Octreotide hGH ( human growth hormone ) History Cardiovascular , Respiratory , Renal/Genitourinary , Gastrointestinal , Neurological/Psychic , cancer Alcoholic , smoker drug abuser Other condition opinion investigator preclude enrollment study</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Safety</keyword>
	<keyword>Male</keyword>
</DOC>